- Details
- In this UroToday discussion between Alicia Morgans and Celestia (Tia) Higano, the pair discuss the REASSURE trial, a phase IV study to further evaluate the safety of radium-223 in the long-term setting. REASSURE is a real-world analysis of pain efficacy of radium-223 treatment among patients with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. Dr. Higano hi...
|
- Details
- Oliver Sartor joins Alicia Morgans and discusses the evolving landscape of BiTE ® technology applied to prostate cancer therapy. BiTE is a bispecific T-cell engaging antibody that binds on PSMA and CD3 on the T cells to activate the T cells. Bispecific T-cell engagers are a novel approach to tumor immunotherapy. They discuss the current clinical trials landscape and what is maybe on the horizon fo...
|
- Details
- In this UroToday discussion, Daniel Petrylak joins Tom Keane highlighting the ESMO 2021 data on CheckMate 9KD cohort A2. This was the final analysis of nivolumab and rucaparib for chemotherapy- naïve metastatic castration-resistant prostate cancer. Biographies: Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology; Co-Leader, Cancer Signaling Networks, Yale Cancer Center,...
|
- Details
- Oliver Sartor joins Alicia Morgans in a real-world data discussion of advanced prostate cancer beginning with highlighting a recent publication looking at outcomes related to the use of radium versus a second novel hormonal agent. The publication is entitled Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC published in Future Oncol...
|
- Details
- In a discussion hosted by Alicia Morgans, Neeraj Agarwal delves into the promising results of the COSMIC-021 study. The study focuses on the combination of cabozantinib and atezolizumab for treating patients with metastatic castrate-resistant prostate cancer (mCRPC). Dr. Agarwal highlights the unique inclusion criteria of the study, which required patients to have progressive measurable disease in...
|
- Details
- Alicia Morgans and Karim Fizazi discuss the VISION trial, evaluating new patient-reported data. This patient-reported health-related quality of life data was presented at ESMO 2021. They discuss the VISION trial design, primary trial endpoints, and the importance of preserving good patient quality of life during advanced prostate cancer treatment. Biographies: Karim Fizazi, MD, Ph.D., is a medical...
|
- Details
- Real-World Safety and Effectiveness of Radium-223 in Japanese Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastasis: Exploratory Analysis, Based on the Results of Post-Marketing Surveillance, According to Prior Chemotherapy Status - Beyond the Abstract. Biographies: Hirotsugu Uemura, Urologist, Chief Professor, Urology Department, Kindai University, Japan Related Content: R...
|
- Details
- In this conversation Tanya Dorff and Alicia Morgans discuss the guidance coming from the NCCN on the use of radium-223 in the metastatic castration-resistant prostate cancer setting, including choosing the right patient for this drug, factors to consider, and the timing of this therapy. As lines of therapy become more complicated with many castration-resistant drugs moving to the hormone-sensitive...
|
- Details
- Phillip Koo and Evan Yu, discuss the phenotypic expression of PSMA. Phenotypic precision medicine guides physicians in looking at the molecular characteristics of a tumor to identify the optimal personalized treatment for the patient. Drs. Yu and Koo discuss the use of PSMA-PET/CT imaging that may fill the critical gaps in prostate cancer staging and as a biomarker for metabolic concordance or res...
|
- Details
- Brenda Martone and Alicia Morgans discuss the positioning of radium-223 in the treatment of patients with bone-only mCRPC. Brenda emphasizes that radium-223 is approved for symptomatic bone-only disease and that this includes many symptoms including fatigue, loss of appetite, and others that are not limited to bone-related pain. This is approved in a broad population and needs to be considered in...
|
